Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst

Posted by Geri Gentry on Aug 18th, 2026

Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) – Research analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for Acrivon Therapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.48) for the quarter, up from their previous estimate of ($0.53). The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.60) EPS.

Separately, Weiss Ratings lowered shares of Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Read Our Latest Research Report on Acrivon Therapeutics

Acrivon Therapeutics Trading Up 5.1%

Acrivon Therapeutics stock opened at $2.05 on Monday. The stock has a market cap of $87.74 million, a PE ratio of -1.09 and a beta of 1.85. The stock has a 50-day moving average price of $1.69 and a 200 day moving average price of $1.68. Acrivon Therapeutics has a 52 week low of $1.27 and a 52 week high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.07.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its holdings in shares of Acrivon Therapeutics by 19.6% during the first quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock worth $1,054,000 after purchasing an additional 124,271 shares during the last quarter. UBS Group AG grew its position in shares of Acrivon Therapeutics by 150,057.8% in the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after purchasing an additional 682,763 shares during the period. Marshall Wace LLP increased its stake in Acrivon Therapeutics by 231.4% in the fourth quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock valued at $1,196,000 after purchasing an additional 346,366 shares during the last quarter. Jane Street Group LLC increased its stake in Acrivon Therapeutics by 18.3% in the fourth quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock valued at $824,000 after purchasing an additional 52,823 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after buying an additional 138,033 shares during the period. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.